Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M. Tolaney(Harvard University), Paolo Tarantino(Dana-Farber Cancer Institute), Noah Graham(Dana-Farber Cancer Institute), Nabihah Tayob(Dana-Farber Cancer Institute), Laia Paré(Oryzon Genomics (Spain)), Guillermo Villacampa(Oryzon Genomics (Spain)), Chau T. Dang(Memorial Sloan Kettering Cancer Center), Denise A. Yardley(Sarah Cannon), Beverly Moy(Massachusetts General Hospital), P. Kelly Marcom(Duke Cancer Institute), Kathy S. Albain(Loyola University Medical Center), Hope S. Rugo(University of California, San Francisco), Matthew J. Ellis, Iuliana Shapira(CancerCare), Antonio C. Wolff(Sidney Kimmel Comprehensive Cancer Center), Lisa A. Carey(UNC Lineberger Comprehensive Cancer Center), Romualdo Barroso‐Sousa(DASA (Brazil)), Patricia Villagrasa(Oryzon Genomics (Spain)), Michelle K. DeMeo(Dana-Farber Cancer Institute), Molly DiLullo(Dana-Farber Cancer Institute), Jorge Gómez Tejeda Zañudo(Broad Institute), Jakob Weiß(Broad Institute), Nikhil Wagle(Dana-Farber Brigham Cancer Center), Ann H. Partridge(Dana-Farber Brigham Cancer Center), Adrienne G. Waks(Harvard University), Clifford A. Hudis(Memorial Sloan Kettering Cancer Center), Ian E. Krop(Yale Cancer Center), Harold J. Burstein(Dana-Farber Brigham Cancer Center), Aleix Prat(Oryzon Genomics (Spain)), Eric P. Winer(Yale Cancer Center)
Cited by 162
Abstract
Related Papers
No related papers found
Powered by citation graph analysis